Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.42 |
| ▸ | TRDMT1 | O14717 | 1/20 | 0.42 |
| ▸ | TYMP | P19971 | 1/20 | 0.42 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.41 |
| ▸ | NNMT | P40261 | 1/20 | 0.40 |
| ▸ | AHCY | P23526 | 3/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | NT5E | P21589 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15048493 | 1.00 | ADORA1 (0.42) | ADORA1TRDMT1TYMPCARM1NNMT | |
| SCHEMBL2106220 | 0.88 | ADORA1 (0.42) | ADORA1TRDMT1TYMPCARM1NNMT | |
| SCHEMBL15841413 | 0.87 | ADORA1 (0.41) | ADORA1TRDMT1TYMPCARM1NNMT | |
| SCHEMBL2107506 | 0.86 | ADORA1 (0.53) | ADORA1TRDMT1TYMPCARM1NNMT | |
| SCHEMBL2213753 | 0.84 | CARM1 (0.34) | ADORA1TRDMT1TYMPCARM1NNMT | |
| SCHEMBL15048538 | 0.84 | CARM1 (0.34) | ADORA1TRDMT1TYMPCARM1NNMT | |
| SCHEMBL2216432 | 0.83 | ST6GAL1 (0.36) | TYMPNT5E | |
| SCHEMBL6835045 | 0.82 | ADORA1 (0.45) | ADORA1TRDMT1TYMPCARM1NNMT | |
| SCHEMBL10690523 | 0.81 | ADORA3 (0.50) | ADORA1TRDMT1TYMPCARM1NNMT | |
| SCHEMBL17599879 | 0.81 | ADORA3 (0.48) | ADORA1TRDMT1TYMPCARM1NNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178284-A1 | Novel protective group for synthesis of RNA and derivative | CHIRALGEN, LTD. (JP) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178284-A1 | Novel protective group for synthesis of RNA and derivative | RNGTT, FBL, RNASEH1 | ADORA1 2387/4885TRDMT1 164/4885TYMP 3514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.